The AcQtrac System is designed to measure cardiac and hemodynamic parameters using impedance cardiography and has 510(k) clearance from the FDA and CE Mark approval in the European Union.
Eden Prairie, Minn.-based CHF Solutions said it plans to evaluate other ways to develop the technology and seek additional clearances “when appropriate” before putting the tech back on the market.
“We believe there is an opportunity to leverage this proprietary technology in conjunction with our Aquadex FlexFlow system by providing clinicians additional hemodynamic information to confidently target how much fluid to remove, manage fluid removal settings, and inform when to stop ultrafiltration,” chairman & CEO John Erb said in prepared remarks. “This acquisition, which did not have a material impact on our cash position, provides further evidence of CHF Solutions’ commitment to becoming the global market leader in fluid management. We look forward to demonstrating that the AcQtrac technology will be an invaluable tool to assist in the management of fluid overloaded patients, in both the inpatient and outpatient clinical settings.”
Last month CHF Solutions said it finished transferring all manufacturing for Aquadex FlexFlow to Eden Prairie. Formely known as Sunshine Heart, the company acquired the Aquadex device in 2016 for $5 million from Baxter (NYSE:BAX).